{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:54:37Z","timestamp":1791179677543,"version":"4.1.0"},"reference-count":52,"publisher":"The Journal of Rheumatology","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2026,5,6]]},"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Imaging biomarkers for disease activity are urgently needed in giant cell arteritis (GCA). Whether 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) can be used to monitor disease activity in patients with large-vessel GCA (LV-GCA) is still unclear. This study aimed to determine how often large-vessel inflammation improves or becomes radiographically quiescent on follow-up PET in patients with LV-GCA who show clinical improvement with treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Medical Literature Analysis and Retrieval System Online (MEDLINE), Embase, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Scopus, and the Cochrane Library were searched from inception through February 29, 2024. Studies describing patients with active LV-GCA on baseline PET who underwent follow-up PET and clinical assessment of disease activity after escalation of immunosuppressive therapy were included. Metaanalysis of the pooled sensitivities of improved PET for clinical improvement and normalized PET for clinical remission in treated patients with GCA was performed, with subgroup analysis of tocilizumab (TCZ)-treated patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 3131 unique references, 25 studies were included. The pooled sensitivity of improved vascular FDG uptake on follow-up PET for clinical improvement in GCA was 0.95 (95% CI 0.82-1.00), and the pooled sensitivity of normalized vascular FDG uptake on follow-up PET for clinical remission was 0.53 (95% CI 0.34-0.72). In TCZ-treated patients, the pooled sensitivity of improvement and normalization of follow-up PET were 1.00 (95% CI 0.99-1.00) and 0.78 (95% CI 0.50-0.97), respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Follow-up PET findings improved in most patients (95%) with LV-GCA who showed clinical improvement with treatment, but large-vessel vasculitis became radiographically quiescent in only 53% of patients. Better responses were observed in those receiving TCZ. (PROSPERO ID: CRD42020219141)<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.2026-0050","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T12:20:12Z","timestamp":1778847612000},"page":"1061-1070","source":"Crossref","is-referenced-by-count":0,"title":["Follow-Up 18F-Fluorodeoxyglucose Positron Emission Tomography in Treated Patients With Giant Cell Arteritis: A Systematic Review and Metaanalysis"],"prefix":"10.3899","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5974-1821","authenticated-orcid":false,"given":"Alison H.","family":"Clifford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4173-5583","authenticated-orcid":false,"given":"JoAnn","family":"Thai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6646-1967","authenticated-orcid":false,"given":"Ashley","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7943-8803","authenticated-orcid":false,"given":"Joanne","family":"Homik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7449-5251","authenticated-orcid":false,"given":"Ben","family":"Vandermeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8676-8675","authenticated-orcid":false,"given":"Janice Y.","family":"Kung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7407-6364","authenticated-orcid":false,"given":"Jan Willem","family":"Cohen Tervaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"2026100422250793000_53.10.1061.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra022694"},{"key":"2026100422250793000_53.10.1061.2","doi-asserted-by":"publisher","DOI":"10.1097\/md.0b013e31803d1764"},{"key":"2026100422250793000_53.10.1061.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2017.04.001"},{"key":"2026100422250793000_53.10.1061.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.21699"},{"key":"2026100422250793000_53.10.1061.5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.0954-6820.1972.tb15615.x","article-title":"Morphological changes in the large arteries in polymyalgia arteritica","volume":"533","author":"Ostberg","year":"1972","journal-title":"Acta Med Scand Suppl"},{"key":"2026100422250793000_53.10.1061.6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13075-023-03254-w","article-title":"Usefulness of 18F-FDG PET-CT for assessing large-vessel involvement in patients with suspected giant cell arteritis and negative temporal artery biopsy","volume":"26","author":"Narv\u00e1ez","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"2026100422250793000_53.10.1061.7","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/art.40876","article-title":"Glucocorticoid dosages and acute-phase reactant levels at giant cell arteritis flare in a randomized trial of tocilizumab","volume":"71","author":"Stone","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026100422250793000_53.10.1061.8","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/art.11388","article-title":"Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes","volume":"49","author":"Proven","year":"2003","journal-title":"Arthritis Care Res"},{"key":"2026100422250793000_53.10.1061.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-3973-8"},{"key":"2026100422250793000_53.10.1061.10","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000622"},{"key":"2026100422250793000_53.10.1061.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213102"},{"key":"2026100422250793000_53.10.1061.12","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/art.40379","article-title":"18F-fluorodeoxyglucose\u2013positron emission tomography as an imaging biomarker in a prospective, longitudinal cohort of patients with large vessel vasculitis","volume":"70","author":"Grayson","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2026100422250793000_53.10.1061.13","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.autrev.2017.09.007","article-title":"Is PET\/CT essential in the diagnosis and follow-up of temporal arteritis?","volume":"16","author":"Salvarani","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2026100422250793000_53.10.1061.14","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00259-018-4021-4","article-title":"Three days of high-dose glucocorticoid treatment attenuates large-vessel 18F-FDG uptake in large-vessel giant cell arteritis but with a limited impact on diagnostic accuracy","volume":"45","author":"Nielsen","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026100422250793000_53.10.1061.15","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224543"},{"key":"2026100422250793000_53.10.1061.16","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1007\/s00259-021-05362-8","article-title":"Diagnostic value of [18F]FDG-PET\/CT for treatment monitoring in large vessel vasculitis: a systematic review and metaanalysis","volume":"48","author":"van Der Geest","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026100422250793000_53.10.1061.17","unstructured":"Covidence systematic review software. [Internet. Accessed May 7, 2026.] Available from: www.covidence.org"},{"key":"2026100422250793000_53.10.1061.18","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-120-11-199406010-00004"},{"key":"2026100422250793000_53.10.1061.19","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/oxfordjournals.qjmed.a068882","article-title":"Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis","volume":"87","author":"Luqmani","year":"1994","journal-title":"QJM Mon J Assoc Physicians"},{"key":"2026100422250793000_53.10.1061.20","doi-asserted-by":"publisher","DOI":"10.1059\/0003-4819-155-8-201110180-00009"},{"key":"2026100422250793000_53.10.1061.21","doi-asserted-by":"publisher","DOI":"10.1136\/jech-2013-203104"},{"key":"2026100422250793000_53.10.1061.22","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-014-2985-3"},{"key":"2026100422250793000_53.10.1061.23","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001417"},{"key":"2026100422250793000_53.10.1061.24","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0248-8663(02)00620-3","article-title":"[Giant cell arteritis and extratemporal arterial involvement: usefulness of 18FDG positron emission tomography. Concerning 3 case reports and a review of the literature]","volume":"23","author":"Belhocine","year":"2002","journal-title":"[Article in French] Rev Med Interne"},{"key":"2026100422250793000_53.10.1061.25","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg317"},{"key":"2026100422250793000_53.10.1061.26","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-003-1144-y"},{"key":"2026100422250793000_53.10.1061.27","first-page":"S21","article-title":"Additional value of positron emission tomography in diagnosis and follow-up of patients with large vessel vasculitides","volume":"22","author":"de Leeuw","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"2026100422250793000_53.10.1061.28","first-page":"S43","article-title":"Cyclophosphamide for large vessel vasculitis: assessment of response by PET\/CT","volume":"29","author":"Henes","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"2026100422250793000_53.10.1061.29","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.149351"},{"key":"2026100422250793000_53.10.1061.30","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker296"},{"key":"2026100422250793000_53.10.1061.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2013.06.004"},{"key":"2026100422250793000_53.10.1061.32","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/RLU.0000000000001016","article-title":"18F-FDG PET\/CT in the management of aortitis","volume":"41","author":"Bruls","year":"2016","journal-title":"Clin Nucl Med"},{"key":"2026100422250793000_53.10.1061.33","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejim.2017.08.013","article-title":"Repetitive 18F-FDG-PET\/CT in patients with large-vessel giant-cell arteritis and controlled disease","volume":"46","author":"de Boysson","year":"2017","journal-title":"Eur J Intern Med"},{"key":"2026100422250793000_53.10.1061.34","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1177\/0003319717753223","article-title":"Tocilizumab in giant cell arteritis: a real-life retrospective study","volume":"69","author":"Vitiello","year":"2018","journal-title":"Angiology"},{"key":"2026100422250793000_53.10.1061.35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/3203241","article-title":"The role of multimodality imaging in monitoring disease activity and therapeutic response to tocilizumab in giant cell arteritis","volume":"2020","author":"Conticini","year":"2020","journal-title":"Mediators Inflam"},{"key":"2026100422250793000_53.10.1061.36","doi-asserted-by":"crossref","first-page":"rkaa017","DOI":"10.1093\/rap\/rkaa017","article-title":"Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients","volume":"4","author":"Regola","year":"2020","journal-title":"Rheumatol Adv Pract"},{"key":"2026100422250793000_53.10.1061.37","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/rheumatology\/keab280","article-title":"Steroid-sparing effect of anakinra in giant-cell arteritis: a case series with clinical, biological and iconographic long-term assessments","volume":"61","author":"Deshayes","year":"2022","journal-title":"Rheumatology"},{"key":"2026100422250793000_53.10.1061.38","doi-asserted-by":"crossref","first-page":"1254747","DOI":"10.3389\/fmed.2023.1254747","article-title":"Mycophenolate mofetil in giant cell arteritis","volume":"10","author":"Pankow","year":"2023","journal-title":"Front Med"},{"key":"2026100422250793000_53.10.1061.39","doi-asserted-by":"crossref","first-page":"152174","DOI":"10.1016\/j.semarthrit.2023.152174","article-title":"Effectiveness of a two-year tapered course of tocilizumab in patients with giant cell arteritis: a single-centre prospective study","volume":"59","author":"Tomelleri","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"2026100422250793000_53.10.1061.40","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.revmed.2013.06.007","article-title":"[Clinical and paraclinical characteristics and disease course of aortic involvement in giant cell arteritis: 26 cases of aortitis among 63 cases of giant cell arteritis]","volume":"35","author":"Daumas","year":"2014","journal-title":"[Article in French] Rev Med Interne"},{"key":"2026100422250793000_53.10.1061.41","doi-asserted-by":"crossref","first-page":"69","DOI":"10.55563\/clinexprheumatol\/mjm8fr","article-title":"Evidence for uncoupling of clinical and 18-FDG activity of PET\/CT scan improvement in tocilizumab-treated patients with large-vessel giant cell arteritis","volume":"39","author":"Prieto Pe\u00f1a","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"2026100422250793000_53.10.1061.42","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead215"},{"key":"2026100422250793000_53.10.1061.43","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s00259-015-3148-9","article-title":"The prognostic value of baseline 18F-FDG PET\/CT in steroid-na\u00efve large-vessel vasculitis: introduction of volume-based parameters","volume":"43","author":"Dellavedova","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026100422250793000_53.10.1061.44","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.181222"},{"key":"2026100422250793000_53.10.1061.45","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejim.2022.08.033","article-title":"Persistent FDG uptake in large vessels and risk of relapse in giant cell arteritis","volume":"106","author":"Eshagh","year":"2022","journal-title":"Eur J Intern Med"},{"key":"2026100422250793000_53.10.1061.46","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1111\/bph.14868","article-title":"Atherosclerosis imaging using PET: insights and applications","volume":"178","author":"Sriranjan","year":"2021","journal-title":"Br J Pharmacol"},{"key":"2026100422250793000_53.10.1061.47","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3259-3"},{"key":"2026100422250793000_53.10.1061.48","first-page":"219","article-title":"Monitoring vasculitis with 18F-FDG PET","volume":"60","author":"Bucerius","year":"2016","journal-title":"Q J Nucl Med Mol"},{"key":"2026100422250793000_53.10.1061.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2021.03.032"},{"key":"2026100422250793000_53.10.1061.50","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1002\/acr.21750","article-title":"Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica","volume":"64","author":"Unizony","year":"2012","journal-title":"Arthritis Care Res"},{"key":"2026100422250793000_53.10.1061.51","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/art.40855","article-title":"Outcomes among 196 patients with noninfectious proximal aortitis","volume":"71","author":"Clifford","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026100422250793000_53.10.1061.52","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S2665-9913(21)00038-2","article-title":"Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the giant cell arteritis Actemra (GiACTA) trial","volume":"3","author":"Stone","year":"2021","journal-title":"Lancet Rheumatol"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2026-0050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:25:59Z","timestamp":1791177959000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2026-0050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":52,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,1]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.3899\/jrheum.2026-0050"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2026-0050","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]}}}